ClinicalTrials.Veeva
Menu

Find clinical trials for Melanoma in Taipei City

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Cancer
Carcinoma
Squamous Cell Carcinoma of Head and Neck
Non-Small-Cell Lung Carcinoma
Renal Cell Carcinoma
Lung Cancer
Squamous Cell Carcinoma

Melanoma trials near Taipei City, TWN:

Nemvaleukin Alfa (ALKS 4230) Monotherapy in Patients With Advanced Cutaneous Melanoma or Advanced Mucosal Melanoma - ARTISTRY-6

This study observes the antitumor activity, safety, tolerability, PK, and pharmacodynamics in patients with inoperable and/or metastatic melanoma...

Enrolling
Mucosal Melanoma
Cutaneous Melanoma
Drug: Nemvaleukin Alfa Intravenous Less Frequent Dosing
Drug: Nemvaleukin Alfa Intravenous

Phase 2

Mural Oncology

Taipei, Taiwan and 40 other locations

(PK) similarity and efficacy, safety, and immunogenicity of ABP 206 compared with OPDIVO® (nivolumab) in subjects with resected advanced melanoma...

Enrolling
Melanoma
Drug: EU-authorized Nivolumab
Drug: ABP 206

Phase 3

Amgen
Amgen

Taipei, Taiwan and 108 other locations

The purpose of this study is to determine whether nivolumab is better than ipilimumab to prevent recurrence of melanoma....

Active, not recruiting
Melanoma
Drug: Nivolumab
Other: Placebo matching Nivolumab

Phase 3

Bristol-Myers Squibb (BMS)
Bristol-Myers Squibb (BMS)

Taoyuan, Taiwan and 135 other locations

is safe and prevents cancer from returning in people with high-risk melanoma. Researchers want to know if V940 with pembrolizumab is better ...

Enrolling
Melanoma
Biological: Pembrolizumab
Biological: V940

Phase 3

Merck Sharp & Dohme (MSD)
Merck Sharp & Dohme (MSD)

Taipei, Taiwan and 145 other locations

The objective of this study is to assess safety and efficacy of CAB-ROR2-ADC in solid tumors

Enrolling
Melanoma
Non Small Cell Lung Cancer
Biological: PD-1 inhibitor
Biological: CAB-ROR2-ADC

Phase 1, Phase 2

BioAtla

Taipei City, Taiwan and 65 other locations

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of KIN-2787 in adults with BRAF/NR...

Enrolling
Melanoma
Solid Tumor, Adult
Drug: KIN-2787 and binimetinib
Drug: KIN-2787

Phase 1

Pierre Fabre
Pierre Fabre

Taipei, Taiwan and 43 other locations

and DKY709 in combination with PDR001 in subjects with NSCLC or melanoma who have received prior anti-PD-1/PD-L1 therapy, or subjects with N...

Active, not recruiting
Melanoma
Nasopharyngeal Carcinoma
Drug: PDR001
Drug: DKY709

Phase 1

Novartis
Novartis

Taipei, Taiwan and 8 other locations

solid tumors. The study is enrolling cohorts of participants with melanoma \[cutaneous/acral\], squamous cell carcinomas of the head and nec...

Enrolling
Melanoma
Endometrial Cancer
Drug: HER3-DXd

Phase 2

Daiichi Sankyo
Daiichi Sankyo

Taipei, Taiwan and 9 other locations

Status recently updated

The purpose of this first in human (FIH) trial is to characterize the safety and tolerability of the SHP2 inhibitor TNO155 alone and in combination w...

Enrolling
Active, not recruiting
Advanced EGFRmutant NonSmallSellLungCancer (NSCLC),KRAS G12-mutant NSCLC,Esophageal SquamousCellCancer (SCC),Head/Neck SCC,Melanoma
Drug: TNO155
Drug: TNO155 in combination with EGF816 (nazartinib)

Phase 1

Novartis
Novartis

Taipei, Taiwan and 18 other locations

The purpose of this study is to characterize the safety and tolerability of KFA115 and KFA115 in combination with pembrolizumab in patients with sele...

Enrolling
Cutaneous Melanoma
Anal Cancer
Drug: KFA115
Drug: pembrolizumab

Phase 1

Novartis
Novartis

Taipei, Taiwan and 12 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems